Phase II trial of procarbazine, vincristine and lomustine (POC) chemotherapy in metastatic cutaneous malignant melanoma
- 31 December 1994
- journal article
- clinical trial
- Published by Elsevier in European Journal Of Cancer
- Vol. 30 (14) , 2054-2056
- https://doi.org/10.1016/0959-8049(94)00273-8
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Treatment of Metastatic Malignant Melanoma with Dacarbazine plus TamoxifenNew England Journal of Medicine, 1992
- Disseminated Malignant Melanoma and Recombinant Interferon: Analysis of Seven Consecutive Phase II InvestigationsJournal of Investigative Dermatology, 1990
- Phase II Study of Recombinant α-Interferon in Malignant MelanomaAmerican Journal of Clinical Oncology, 1990
- Phase II Study of Interferon α-2a and Dacarbazine in Advanced MelanomaAmerican Journal of Clinical Oncology, 1990
- A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanomaCancer, 1989
- Treatment of metastatic malignant melanoma with dacarbazine, vindesine and cisplatinBritish Journal of Cancer, 1989
- High-dose, double alkylating agent chemotherapy with DTIC, melphalan, or ifosfamide and marrow rescue for metastatic malignant melanomaCancer, 1989
- Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma IV. Late results after complete response to chemotherapy (central oncology group protocols 7130, 7131, and 7131A)Cancer, 1984
- Reporting results of cancer treatmentCancer, 1981
- Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examplesBritish Journal of Cancer, 1977